Citi Upgrades Acorda Therapeutics, Inc. (ACOR) to Buy
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Price: $0.66 --0%
Rating Summary:
4 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 52
Rating Summary:
4 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 52
Join SI Premium – FREE
Citi upgraded Acorda Therapeutics, Inc. (NASDAQ: ACOR) from Hold to Buy, price target lowered from $36 to $25.
For more ratings news on Acorda Therapeutics, Inc. click here and for the rating history of Acorda Therapeutics, Inc. click here.
Shares of Acorda Therapeutics, Inc. closed at $19.21 yesterday.
For more ratings news on Acorda Therapeutics, Inc. click here and for the rating history of Acorda Therapeutics, Inc. click here.
Shares of Acorda Therapeutics, Inc. closed at $19.21 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades PulteGroup (PHM) to Outperform
- Seaport Global Securities Upgrades Analog Devices (ADI) to Buy, 'appears to be entering the sweet part of the cycle'
- Citigroup set to join top banks in Anthropic IPO - Bloomberg
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
